Zepp Health (NYSE:ZEPP) Given a $56.28 Price Target at Fundamental Research

Zepp Health (NYSE:ZEPP) has been given a $56.28 price objective by analysts at Fundamental Research in a note issued to investors on Wednesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Fundamental Research’s price objective would indicate a potential upside of 241.82% from the stock’s current price.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zepp Health in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zepp Health currently has an average rating of “Hold” and an average price target of $56.28.

Zepp Health Stock Up 9.9%

ZEPP stock traded up $1.49 on Wednesday, reaching $16.47. 40,686 shares of the company traded hands, compared to its average volume of 115,707. Zepp Health has a one year low of $2.22 and a one year high of $61.85. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.02 and a quick ratio of 0.77. The company has a market cap of $238.74 million, a P/E ratio of -6.56 and a beta of 1.76. The firm has a fifty day simple moving average of $17.11 and a 200-day simple moving average of $26.15.

Institutional Trading of Zepp Health

A number of institutional investors and hedge funds have recently modified their holdings of ZEPP. FIL Ltd bought a new stake in shares of Zepp Health in the 4th quarter worth $16,858,000. Trivest Advisors Ltd bought a new stake in shares of Zepp Health in the 3rd quarter worth $13,503,000. Millennium Management LLC bought a new stake in shares of Zepp Health in the 3rd quarter worth $11,265,000. UBS Group AG increased its holdings in shares of Zepp Health by 16,412.0% in the 3rd quarter. UBS Group AG now owns 181,302 shares of the company’s stock worth $8,300,000 after purchasing an additional 180,204 shares in the last quarter. Finally, Monolith Management Ltd bought a new stake in shares of Zepp Health in the 4th quarter worth $3,601,000. Institutional investors own 52.61% of the company’s stock.

About Zepp Health

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.